The discoveries that it increases renal blood flow-8 and decreases cerebral vascular resistance'9 concomitantly with fall in systemic blood pressure lent (onsiderable interest to this agent. The rise in renal blood flow is associated with increased cardiac output and tachycardia ;20 21 the latter effects can be presented by prior admifnistration of hexamethonium.2 Subsequent clinical investigations7' [23] [24] [25] [26] [27] [28] have shown, with few exceptions, 29' 30 that hydralazine employed ( oncurrently with hexamethonium is more effective in the treatment of hypertension than either agent used alone. The present investigation was begun ill an effort to study the effects of combined hexamethonium-hydralazinie therapy in the longterm treatment of severe hypertension. Its purpose was two-fold: (1) to determine whether the combination of hexamethonium and hydralazine would be more effective than hexamethonium alone in controlling hypertensive disease (a) when hydralazine was added after months of hexamethonium administration, or (b) when administration of the two agents was begun concomitantly; and (2) In assessing the efficacy of therapy in controlling blood pressure, two methods of approach were used. First, for each treatment period the patients were separated into three arbitrary, previously defined groups,l group A, "good," group B, "fair," group C, "pooi'," accorlcing to recumbent blood pressure .;LE attributed to hydralazine; the other complications were ascribed to the severity of the hypertensive disease itself. Seven of the 61 patients, one in series I and six in series II, developed late systemic reactions to hydralazine which necessitated discontinuance of the drug in each instance. Six of these reactions were characterized by symptoms and signs suggestive of rheumatoid arthritis; and one patient exhibited, in addition, pleuritis with effusion, pericarditis with effusion, fever, and "L.E." cells in the peripheral blood. The features of these reactions are presented in detail elsewhere.33
Effect Upon Blood Pressure Table 2 presents the blood pressure responses of all 61 patients treated with hexamethonium and hydralazine in combination, according to the arbitrarily defined groups A, B, C. Fifty of the 61 patients continued combined therapy for five months or longer and were satisfactorily followed. Thirty of the 31 patients in series I had been treated with hexamethonium alone for five months or longer before hydralazine was added. The failure of hexamethonium alone to maintain good control of blood pressure, except for one of 30 patients, throughout prolonged therapy is apparent in table 2. This loss of blood pressure control occurred despite increases in dosage of hexamethonium to maximum tolerated levels in each patient. The addition of hydralazine to these same patients in series I, however, resulted in far better control of blood pressure during prolonged observation. Ten of 26 control of blood pressure demonstrated a significant decrease in heart size, and two patients with "poorly" controlled blood pressure exhibited a definite increase in heart size. In series I after the addition of hydralazine and during combined therapy no patient demonstrated a significant increase or decrease in heart size. In series II during combined hexamethonium-hydralazine therapy two patients, both of whom initially were in congestive heart failure and subsequently had "poor" control of blood pressure, showed a significant decrease in heart size, while one patient with "poor" blood pressure control exhibited a significant increase in heart size.
Effect L pon Electrocardiogram Thirty-six patients, 18 in each series, demonstrated ST-T changes of "left ventricular strain pattern" prior to therapy. In series I during treatment with hexamethoniuim alone, four patients showed improvement in the "strain pattern", and in three of these the ST-T changes reverted entirely to normal. After addition of hydralazine to this group and during combined therapy, four patients demonstrated improvement in the ST-T pattern, with reversion to normal in two instances, while one patient demonstrated an increase in the "strain pattern". In series II during combined therapy 8 of 18 abnormal electrocardiograms improved, and in six of these there was a complete reversal of the ST-T "strain pattern" to normnal.
Effect Upon Renal Function
Before treatment 36 patients (15 in series I and 21 in series II) showed proteinuria, and eight patients (three in series I and five in series II) exhibited impaired renal function as measured by the standard laboratory tests. In series I, during therapy with hexamethonium alone, one patient developed impairment of renal function which subsequently progressed and two patients developed slight proteinuria. In both series, during combined hexamethonium-hydralazine therapy, three patients with impaired renal function (two in series I and one in series II) exhibited progressive impairment of function terminating in renal insufficiency and death in uremia. During combined therapy one patient in series I developed slight proteinuria. DiscussioN
Hexamethonium and hydralazine administered simultaneously constitute a potent combination of hypotensive drugs, capable of achieving and maintaining for prolonged periods significant reduction of blood pressure in the majority of patients exhibiting severe hypertensive vascular disease. Previous extended experiences with hexamethonium administered alone indicated this compound to have limited utility in severe hypertensive disease because of the gradual loss of blood pressure control after months of continued therapy. The addition of hydralazine to a group of patients responding poorly to long-term hexamethonium treatment resulted in further reduction of mean blood pressure and more satisfactory control of blood pressure for most individuals. In these patients it permitted reduction in average daily dosage of hexamethonium; slight amelioration of the side-effects from hexamethonium followed. No appreciable difference was noted in the final results between the late and early addition of hydralazine to hexamethonium. therapy, although in the latter instance initial effects upon blood pressure were better due to earlier titration of hydralazine dosage. During combined therapy no tendency for blood pressure control to "escape" was evident after months of uninterrupted therapy.
Especially gratifying were the responses of nine patients suffering from malignant hypertension, four of whom had impaired renal function and three of whom had nitrogen retention. The rice diet, later modified to standard low sodium diet, wN-as used initially in all nine patients. Eight patients exhibited reversal of the malignant phase, one while receiving hexamethonium alone, and seven during combined treatment, initially instituted. Two of the nine patients subsequently died; one patient responded poorly to therapy and died of uremia and possible hexamethonium poisoning; the other succumbed to subarachnoid hemorrhage from cerebral aneurysm several months after discontinuing both drugs. It has been our experience that the young malignant hypertensive patient who possesses good renal function is particularly sensitive and responsive to combined drug and dietary therapy. Our observations generally are in accord with those reported by Schroeder.27 34 Dietary restriction of sodium has been demonstrated to potentiate the hypotensive effect of hexamethonium,26 and hydralazine2 35 used separately. Sodium restriction may have played some part in decreasing blood pressure in many of our patients. Its exact contribution is difficult to assess in a clinical study of this type.
During combined hexamethoinium-hydralazine therapy, approximately one-fifth (20 per cent) of all patients exhibited improvement in retinopathy and in the electrocardiogram. It is to be noted that improvement in retinopathy and in the electrocardiogram had already occurred in a significant number of patients in series I during treatment with hexamethonium alone; hence the addition of hydralazine produced relatively little further change in these areas. Little effect was noted either upon heart size or renal function during combined therapy.
Although (4) The late addition of hydralazine to hexamethonium produced equally good eventual blood pressure reduction and control as did the initial combination of the two drugs; in the latter instance, however, better results during combined therapy were achieved earlier.
(5) Improvement in retinopathy and in the electrocardiogram occurred in one-fifth of all patients during combined therapy, while little appreciable effect upon renal function or heart size was noted.
(6) Vascular complications incident to the hypertensive process were not prevented by therapy. Seven deaths (11 per cent) occurred, only one of which was attributed to the drugs. Six nonfatal complications also appeared during treatment.
(7) Late systemic reactions to hydralazine were observed in seven (11 per cent) patients; in one patient the illness simulated disseminated lupus erythematosus and necessitated corticotropin and cortisone therapy.
(8) Combined hexamethonium-hydralazine therapy together with rigid dietary restriction of sodium constitutes at present an effective form of treatment for malignant hypertension and severe essential hypertension when renal function is good. The hazard of late systemic reactions to hydralazine limits the usefulness of this drug in the long-term therapy of hypertension. SUMMARIO 
